Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Retail: premium finishes, tactile closures
Semaglutide the original ~14.9% average body-weight reduction at 52 weeks Targets GLP-1 (one pathway) Weekly injection Best for: first-timers, or anyone sensitive to side effects Tirzepatide the upgrade ~22.1% average body-weight reduction at 52 weeks Targets GLP-1 + GIP (two pathways) Weekly injection Best for: plateaued on semaglutide, or want stronger results Retatrutide the newest ~25.9% average body-weight reduction at 52 weeks Targets GLP-1 + GIP + glucagon (three pathways) Weekly injection Best for: want the newest science, comfortable with a compounded option Semaglutide: the original Semaglutide is a GLP-1 receptor agonist
doi: 10.1056/NEJMc1107080
Always re-verify coverage at the start of each plan year
US$ 27.38
US$ 28.29
US$ 22.28
US$ 25.40
